BORA - UiB

Bergen Open Research Archive

The cost of multiple sclerosis in Norway

Bergen Open Research Archive

Show simple item record

dc.contributor.author Svendsen, Bjørn eng
dc.contributor.author Myhr, Kjell-Morten eng
dc.contributor.author Nyland, Harald Inge eng
dc.contributor.author Aarseth, Jan Harald eng
dc.date.accessioned 2011-03-11T10:03:17Z
dc.date.available 2011-03-11T10:03:17Z
dc.date.issued 2010-11-16 eng
dc.identifier.citation The European Journal of Health Economics 1-11 en_US
dc.identifier.issn 1618-7598 eng
dc.identifier.uri http://hdl.handle.net/1956/4568
dc.description.abstract Health economic aspects have been increasingly important during introduction of new treatments for multiple sclerosis. As a partial response for Norway, a costof- illness study was carried out to estimate the yearly cost of the illness to society and relate costs and patients’ quality of life to illness severity. Estimated cost to society was Euro 439 million in 2002 exclusive of the cost of reduced quality of life. The cost per patient was close to Euro 65,000. Account taken of methodological differences, the results compare to results for Sweden, Norway’s closest neighboring country. The illness reduced patients’ quality of life with 0.26. More patients were early retired because of their MS in Norway than in any of nine other European countries comprised by a recent European study, illustrating a liberal practice in Norway. The Norwegian cost of unpaid assistance was almost identical to the Swedish cost that was the lowest found across the countries in the European study. When related to illness severity, the cost per patient increased, and the patients’ experienced quality of life decreased with increasing EDSS levels in line with what has been found for other countries. Cost-of-MS studies have been carried out for a number of countries. Together they contribute to our understanding of the economic consequences of multiple sclerosis and, if their results are related to illness severity, also provide valuable information for further economic analyses of treatment and medication. Our study adds to this. en_US
dc.language.iso eng eng
dc.publisher Springer eng
dc.rights Attribution-NonCommercial CC BY-NC eng
dc.rights.uri http://creativecommons.org/licenses/by-nc/2.5/ eng
dc.subject Multiple sclerosis eng
dc.subject Cost-of-illness eng
dc.subject Quality of life eng
dc.subject Relapse eng
dc.subject EDSS eng
dc.subject Norway eng
dc.title The cost of multiple sclerosis in Norway eng
dc.type Peer reviewed eng
dc.type Journal article eng
dc.subject.nsi VDP::Medical disciplines: 700 eng
dc.rights.holder Copyright The Author(s) 2010. This article is published with open access at Springerlink.com
dc.rights.holder The Author(s) 2010 eng
dc.type.version publishedVersion eng
bora.peerreviewed Peer reviewed eng
bora.cristinID 922561 eng
bibo.doi http://dx.doi.org/10.1007/s10198-010-0286-7 eng
dc.identifier.cristinID 922561 eng
dc.identifier.doi http://dx.doi.org/10.1007/s10198-010-0286-7


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC

Search BORA


Browse

My Account